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Abstract. – OBJECTIVE: Information on the 
long-term safety of electronic cigarettes (e-cig) 
is still limited. We report the results after six 
years of follow-up of the first observational 
study assessing e-cig long-term effectiveness 
and safety. 
PATIENTS AND METHODS: Participants 
were adults who smoked ≥1 tobacco cigarette/
day (tobacco smokers); or used any type of 
e-cig inhaling ≥50 puffs weekly (e-cig users); 
or used both (dual users). Participants were 
contacted directly or by phone and/or internet 
interviews. Hospital discharge abstract data and 
carbon monoxide level tests were also used.
RESULTS: Data were available for 228 e-cig 
users (all ex-smokers), 469 tobacco smokers, 
215 dual users. A possibly smoking-related dis-
ease (PSRD) was recorded in 90 subjects (9.9%); 
11 deceased (1.2%). No differences were ob-
served across groups in PSRD rates, with minor 
changes in self-reported health. Among e-cig 
users, 64.0% remained tobacco abstinent. Dual 
users and tobacco smokers did not significantly 
differ in the rate of cessation of tobacco (38.6% 
vs. 33.9%, respectively) and all products (23.7% 
vs. 26.4%). A comparable decrease in daily cig-
arettes was also observed. 39.5% of the sample 
switched at least once (tobacco smokers: 15.1%; 
dual users: 83.3%).
CONCLUSIONS: After six years, no evidence 
of harm reduction was found among e-cig or 
dual users. The complete switch to e-cig might 
support tobacco quitters remain abstinent, but 
the use of e-cig in addition to tobacco did not 
improve smoking cessation or reduction.
Key Words:
Electronic cigarettes, Traditional smoking devices, 
Heat-not-burn products, Smoking cessation, Harm re-
duction, Tobacco smoking, Adverse health effects.
Introduction
In spite of the widespread consensus on the 
necessity for additional data on electronic ciga-
rette (e-cig) long-term effectiveness and safety 
to support public health policies1-12, uncertainty 
remains13,14. Despite the alarming emergence of 
observational evidence of lung injuries15-17 and 
altered cardiovascular parameters18 in the short-
term, the available information on long-term 
safety is limited to a large observational cohort 
with only self-reported data after 3 years of fol-
low-up19, and nine healthy vapers, non-former 
smokers, who were followed for 3.5 years20.
Concerning effectiveness, numerous studies 
with short follow-up are available1,3-8,11,21-30, the 
results are conflicting14,22,29,31, and long-term data 
are still lacking. Finally, scarce longitudinal data 
are also available on e-cig patterns of use over 
time29,32-34.
In 2013, we initiated the first longitudinal co-
hort study to evaluate the long-term effectiveness 
and safety of e-cig through a direct comparison 
with tobacco cigarette smokers35. We previously 
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published the results of the 12-, 24-, and 48-month 
follow-up36-38; and we are here updating the analy-
ses with the main findings of the 6-year follow-up.
Patients and Methods 
The protocol has been registered on Clinical-
trials.gov (NCT01785537), and published35. Brief-
ly, participants were adults (30-75 years) who, 
since ≥6 months: smoked only tobacco cigarettes 
(≥1 per day – tobacco smokers), or used any type 
of e-cig (e-cig users), or used both tobacco and 
e-cig (dual users). The recruitment was based on 
general practitioners, internet advertisements and 
social networks, and e-cig shops. Participants’ 
information was collected through a structured 
questionnaire, administered directly or by phone 
and/or internet interviews.
The outcomes of effectiveness were: (a) the 
rate of quitting of all products (either tobacco 
and/or e-cig, since 30 days or more); (b) the rate 
of abstinence (for e-cig users) and cessation from 
tobacco smoking (for the other two groups) at 72 
months; and (c) the difference in the number of 
tobacco cigarettes per day. To check the absti-
nence from tobacco, we tested carbon monoxide 
levels in expired breath (Smokerlyzer® piCO+™, 
Bedfont Scientific Ltd., Station Road, Harrietsh-
am, Maidstone, Kent, UK) in a random sample 
of 50% of the subjects declaring tobacco smoking 
abstinence.
The safety (health) outcomes were: (a) the rate 
of possibly smoking-related diseases (PSRD, in-
cluding chronic obstructive pulmonary disease, 
myocardial infarction and/or angina, congestive 
heart failure, transitory cerebrovascular ischemia 
or stroke, any cancer); and (b) the variation in 
self-reported health (assessed via the final item of 
the Italian version of the EuroQol EQ-D5L39,40). 
Allergies and/or mouth irritation were also eval-
uated separately from other safety outcomes. 
Safety data were both self-reported and collected 
through direct contact (for the Sicilian residents 
– 16.0% of the sample) or hospital discharge ab-
stracts (for the Abruzzo residents – 46.8%). The 
last data collection was carried out after 72±3 
months since the enrollment.
The Ethics Committee of the University of 
Chieti-Pescara approved the protocol (Record n. 
6; 25-03-2013). A written informed consent was 
obtained by all participants, and the entire dataset 
is available upon request from the authors.
Data Analysis
In long, observational studies, a substantial 
proportion of participants typically change their 
exposure status during the follow-up41,42. As an 
example, tobacco smokers can switch to e-cig, 
and vice versa. Real-life studies in this field pres-
ent some additional complexities, because the 
outcome of quitting smoking/vaping is not stable, 
and can also change over time. Consequently, the 
classical analytical approach, where participants 
are classified only according to their baseline ex-
posure status (similar to an Intention-to-treat ap-
proach - ITT - which is instead the best approach 
for randomized trials with stable final outcomes 
and group switching rate infrequently exceed-
ing 10%), must be complemented with additional 
analyses that take into account switching and “re-
al-life” group assignments. Thus, a stringent ITT 
approach was not followed, and the participants 
who did not provide any data at any follow-up as-
sessment were not included in the analyses. We 
used the following three analytical approaches, 
with a decreasing similarity with ITT:
(A1) The exposure group was determined ac-
cording to the baseline smoking/vaping status 
(regardless of switching), and the analyses in-
cluded all participants providing data at the first, 
12-month follow-up (n=959). This analytical ap-
proach was used for the categorical outcomes of 
effectiveness.
(A2) The exposure group was assigned accord-
ing to the baseline status (regardless of switch-
ing), but only those who were followed up to 72 
months were analyzed (n=912). Remarkably, only 
one PSRD was observed in previous assessments 
among the 47 participants that were lost during 
previous follow-ups. This analytical approach was 
adopted for the assessments of all the outcomes.
(A3) The exposure group was determined ac-
cording to the baseline status, but only the partic-
ipants who provided data at 72 months and never 
switched smoking/vaping status were included in 
the analyses. Notably, quitting was not judged as 
a switch, and this approach was adopted for all 
safety outcomes and the continuous outcome of 
effectiveness.
In order to investigate the potential indepen-
dent predictors of continuous and categorical 
outcomes, we used, respectively, multivariate 
random-effect linear and logistic regressions43,44, 
with geographical region as the cluster unit. We 
set a multivariate model for each of the above 
three analytical approaches. The following base-
line characteristics were included a priori into the 
Safety and effectiveness of e-cigarettes after 6 years
3925
models predicting effectiveness outcomes: age, 
gender, BMI, marital status, educational level, 
occupation, alcohol use, hypertension, hypercho-
lesterolemia, diabetes mellitus, self-rated health, 
smoking/vaping amount, and years of tobacco 
smoking. The models predicting safety (health) 
outcomes were adjusted only for age, gender, 
self-rated health, years of tobacco smoking, and 
hypertension (all of which showed a p-value <0.2) 
to reduce overfitting. No missing data imputation 
technique was adopted, because missing data 
were <1% for all variables. Significance was set 
at 0.05 (two-tailed) for all analyses, which were 
carried out using Stata 13.1 (Stata Corp., College 
Station, TX, USA, 2014).
Results
Of the 1355 enrolled subjects, 959 provided 
data at least once (70.8%) and were included in 
the analytical approach A1 (Figure 1). After six 
years of follow-up, data were available for a to-
tal of 912 subjects (50.4 years on average, 56.3% 
males). According to baseline status, 228 were 
e-cig users, 469 tobacco smokers, and 215 dual 
users. These subjects were included in the analyt-
ical approach A2.
Health Outcomes
A PSRD was recorded in 90 subjects (9.9%), 
with no significant differences by baseline group: 
11.4%, 8.1% and 12.1% PSRD were observed 
among baseline e-cig users, tobacco smokers, 
and dual users, respectively (Table I, analyti-
cal approach A2). Similar results were observed 
when the analyses were restricted to non-switch-
ers (Table I, A3). Also, no significant differences 
were found when only cancers (n=40 overall), or 
mouth irritation (n=43) were considered, both in 
the complete and restricted sample. Moreover, 
self-reported health showed a very small change 
over time in all groups (Table I).
The results did not differ substantially when the 
sample was restricted to the 285 participants who 
did not switch smoking/vaping group, and were 
visited or had their outcomes confirmed through 
a linkage with hospital discharge abstracts: as 
compared with tobacco smokers, PSRD or cancer 
rates were lower among e-cig or dual users, but 
the differences were still not significant (Table I).
Multivariate analyses entirely confirmed uni-
variate results (Table II). Overall, 11 deaths were 
registered during the six years of follow-up: 3 
among tobacco smokers, 5 among e-cig users, 
and 3 among dual users (p>0.2).
Outcomes of Effectiveness
A total of 64.0% of the baseline e-cig users re-
mained abstinent from tobacco smoking during 
the six years of follow-up. Among baseline to-
bacco smokers and dual users, 33.9% and 38.6% 
achieved tobacco abstinence, respectively (p<0.05 
only for the difference between e-cig users and 
the other groups; Table III, analytical approach 
A2). No differences across baseline groups were 
found in the proportion of subjects who quit either 
tobacco and/or e-cigarettes: 26.3%, 26.4% and 
23.7% achieved complete abstinence among e-cig 
users, tobacco smokers and dual users, respec-
tively (all p>0.05; Table III, A2). Both outcomes 
showed similar results when the larger, 12-month 
sample was used (Table III, A1). 
A significant decrease in the mean number of 
tobacco cigarettes smoked daily was observed 
among both dual users and tobacco smokers, but 
the reduction was only slightly higher among dual 
users (-6.0 vs. -5.2, respectively; Table III, A2). 
When the analyses were repeated, including only 
the subjects who did not switch (Table III, A3), the 
dual users showed a significantly larger reduction, 
as compared to tobacco smokers, of the daily num-
ber of tobacco cigarettes (-11.5 vs. -4.2, p<0.001). 
Again, the multivariate analyses substantially con-
firmed the univariate results (Table IV).
Switching Smoking/Vaping Status, 
and Pathway of Use Through 
the Follow-Up
The participants that changed their expo-
sure status (e.g., from e-cig only to dual use) at 
least once during the follow-up were defined as 
“switchers”. Quitting all products was not de-
fined as “switching”, because this is an outcome 
of effectiveness. The smoking/vaping pathway of 
all participants during the follow-up, including 
switching category (yes or no), have been report-
ed in the Supplementary Figure 1: 39.5% of the 
participants switched product during the six years 
of follow-up, with wide differences across groups: 
15.1% of tobacco smokers; 48.2% of e-cig users; 
and 83.3% of dual users. As a consequence, the 
analyses restricted to those who never switched 
were based on a scarce number of e-cig users 
(n=118) and dual users (n=36), and the results 
should be interpreted with caution (Tables III and 
IV, analytical approach A3).
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Figure 1. Flow of the participants and numbers of quitters and possibly-related serious adverse events.
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Concerning smoking/vaping pathways, of the 
343 subjects who switched smoking/vaping group 
at the 12-, 24- or 48-month assessments, 32.9% 
(n=113) switched group again during the fol-
low-up. Among the 62 baseline tobacco smokers 
who changed status, 45 initially switched to e-cig 
use only. Of them, 26 remained abstinent from 
tobacco, whereas 19 switched back to tobacco 
(only, or dual use). Among the 105 baseline e-cig 
users that changed status, 72 made the first switch 
to tobacco smoking only. After this switch, only 
15 subjects made an additional attempt to quit 
tobacco. Among the 176 baseline dual users that 
changed status, 141 made the first switch to to-
bacco smoking only (114 of them switched after 
12 months of follow-up). After this switch, only 
30 participants made another attempt to cease 
smoking.
With regard to the rate of quitting (of all prod-
ucts) failures, more than half of the participants of 
all groups were able to maintain abstinence after the 
first quit attempt: 64.8% (94/145) among those who 
quit from tobacco (only) smoking; 78.1% (50/64) 
among e-cig users; 61.1% (22/36) among dual users.
A total of 514 subjects used e-cig at least once 
during the follow-up (including both e-cig users 
and dual users at baseline, and those who were 
tobacco smokers at baseline and then switched to 
e-cig or dual use during the follow-up). Of them, 
505 tried e-cig during 12-, 24-, or 48-month fol-
low-up assessments, and 121 (24.0%) were able to 
quit the use of all products. A slightly higher ces-
sation rate (28.0%) was observed among the 407 
participants who never used e-cig during previous 
follow-up evaluations.
Discussion
This report summarizes the longest available ev-
idence on e-cig safety and effectiveness vs. tobacco 
smoking, adding important confirmation to previous 
results36-38, and describing “real-world” vaping and 
smoking pathways for more than a quinquennium. 
Table I. Rates of possibly smoking-related diseases ψ during the follow-up.
ψChronic obstructive pulmonary disease (COPD), myocardial infarction and/or angina, congestive heart failure, transitory 
cerebrovascular ischemia or stroke, any cancer. All p-values for the comparisons between groups were not significant: they were 
thus not shown.
 E-cig. Tobacco cig. Dual use
 % (n/N) % (n/N) % (n/N)
Any possibly smoking-related disease   
  A2. Analyses by baseline status, including only the participants  11.4 (26/228) 8.1 (38/469) 12.1 (26/215)
    with 6-year follow-up data 
  A3. Analyses restricted to non switchers only, with all data 10.2 (12/118) 8.5 (34/398) 11.1 (4/36)
    at 72 months 
   
Analyses further restricted to the participants with a visit 
 or hospital discharge data available   
  A2. 12.0 (25/208) 13.1 (26/198) 14.6 (24/164)
  A3. 10.0 (11/110) 15.4 (23/149) 15.4 (4/26)
   
Cancer   
  A2. 6.6 (15/228) 3.6 (17/469) 3.7 (8/215)
  A3. 5.1 (6/118) 3.8 (15/398) 5.6 (2/36)
   
Analyses further restricted to the participants with a visit 
 or hospital discharge data available   
  A2. 6.7 (14/208) 6.6 (13/198) 4.3 (7/164)
  A3. 4.6 (5/110) 8.0 (12/149) 7.7 (2/26)
   
Mouth irritation   
  A2. 6.6 (15/228) 4.5 (21/469) 3.3 (7/215)
  A3. 6.8 (8/118) 3.5 (14/398) 0.0 (0/36)
   
Self-rated health – Mean difference baseline-6 years Mean (SD) Mean (SD) Mean (SD)
  A2. -0.1 (1.9) -0.1 (1.5) 0.0 (1.8)
  A3. -0.2 (1.8) -0.1 (1.4) +0.2 (2.1)
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Table II. Multivariate analyses on possibly smoking-related diseases and self-reported health.
AMultivariate random-effect logistic regression, with geographical region as the cluster unit, adjusted for baseline age, gender, 
self-rated health, years of tobacco smoking and hypertension.
BMultivariate random-effect linear regression, with geographical region as the cluster unit, adjusted for baseline age, gender, 
BMI, marital status, educational level, occupation, alcohol use, hypertension, hypercholesterolemia, diabetes, self-rated health, 
smoking/vaping amount, and years of tobacco smoking.
Outcomes Adjusted OR (95% CI) pA
Possibly smoking-related disease  
A2. Analyses by baseline status, including only the participants 
 with 6-year follow-up data  
 – Tobacco smokers (ref. cat.) 1 (–) –
 – E-cig. users 1.17 (0.64-2.13) 0.6
 – Dual users 1.48 (0.81-2.70) 0.2
  
A3. Analyses restricted to non switchers only, with all data at 72 months  
 – Tobacco smokers (ref. cat.) 1 (–) –
 – E-cig. users 0.88 (0.40-1.93) 0.7
 – Dual users 1.28 (0.38-4.31) 0.7
  
Self-rated health score
Difference baseline-6 years Adj. coefficient (95% CI) pB
A2. Analyses by baseline status, including only the participants 
 with 6-year follow-up data  
 – Tobacco smokers (ref. cat.) 0 (–) –
 – E-cig. users -0.19 (-0.42; 0.05) 0.12
 – Dual users 0.16 (-0.08; 0.39) 0.19
  
A3. Analyses restricted to non switchers only, with all data at 72 months  
 – Tobacco smokers (ref. cat.) 0 (–) –
 – E-cig. users -0.24 (-0.62; 0.14) 0.2
 – Dual users 0.43 (-0.33; 1.19) 0.3
Table III. Cigarette use after six years of follow-up.
*p-values that were significant at univariate analyses (using chi-squared test for categorical variables; t-test for continuous ones). 
If not reported, p-values are >0.05. AE-cig. only vs. tobacco cig. only. BE-cig. only vs. dual use.  CTobacco cig. only vs. dual use.
 E-cig. Tobacco cig. Dual use p* 
 % (n/N) % (n/N) % (n/N) 
Quitting any product (tobacco and/or e-cigarettes)    
  A1. Analyses by baseline status, including the larger  26.7 25.9  22.4 
    12-month sample (63/236) (127/491) (52/232) 
  A2. Analyses by baseline status, including only the  26.3  26.4  23.7
    participants with 6-year follow-up data (60/228) (124/469) (51/215) 
Continuous tobacco abstinence from baseline or cessation from tobacco during follow-up 
  A1. Analyses by baseline status, including the larger 64.4  33.0 36.6 <0.001A;
    12-month sample (152/236) (162/491) (85/232) <0.001B
  A2. Analyses by baseline status, including only the  64.0 33.9 38.6 <0.001A;
    participants with 6-year follow-up data (146/228) (159/469) (83/215) <0.001B
    
Number of tobacco cigarettes per day -  E-cig. Tobacco cig. Dual use p* 
 Mean difference 4y-baseline % (n/N) % (n/N) % (n/N)
  A2. Analyses by baseline status, including only  – -5.2 (9.5) -6.0 (11.7)
    the participants with 6-year follow-up data  
  A3.Analyses restricted to non switchers only,  – -4.2 (9.2) -11.5 (10.8) <0.001C
    with all data at 72 months 
Safety and effectiveness of e-cigarettes after 6 years
3929
First, after six years of follow-up, no evidence of 
harm reduction emerged among e-cig users, as 
compared to tobacco smokers. This finding was 
consistent for all health outcomes (including can-
cer), and across all analytical approaches. Addi-
tionally, e-cig use did not substantially improve 
self-reported health. Our results are in line with 
those of several prior studies, all suggesting the 
absence of a net health benefit among e-cig users 
when compared to traditional tobacco smokers 
19-21,24-26,45-49, while other studies outlined poten-
tial positive effects of e-cig in the regulation of 
cardiovascular18,50, or laboratory32,51-53 parameters. 
However, the interpretation of these studies must 
take into account the short duration of their fol-
low-up, never exceeding 3.5 years20, while any 
decrease in the excess risk of tobacco smoking 
may take a minimum of five years to emerge54. 
Thus, the strength of the evidence either in favor 
or against any harm reduction resulting from the 
exclusive use of e-cig was severely limited, and 
additional long-term data were strongly awaited. 
In this scenario, although the present findings 
add further evidence, additional studies with 
even longer follow-ups are required: in a sample 
composed by former smokers, a decade would be 
more appropriate to detect significant risk reduc-
tions for cancers or cardiovascular diseases54. 
Second, although the complete switch to e-cig 
confirmed to help tobacco quitters to remain ab-
stinent from smoking, with six-year relapse rates 
lower than 40%, the use of e-cig in addition to 
tobacco smoking (dual use) proved to be only 
marginally useful to promote smoking cessation: 
AMultivariate random-effect logistic regression, with geographical region as the cluster unit, adjusted for baseline age, gender, 
BMI, marital status, educational level, occupation, alcohol use, hypertension, hypercholesterolemia, diabetes, self-rated health, 
smoking/vaping amount, and years of tobacco smoking.
BMultivariate random-effect linear regression, with geographical region as the cluster unit, adjusted for baseline age, gender, 
BMI, marital status, educational level, occupation, alcohol use, hypertension, hypercholesterolemia, diabetes, self-rated health, 
smoking/vaping amount, and years of tobacco smoking.
Table IV. Multivariate analyses predicting tobacco and/or e-cig use abstinence and/or cessation, and the difference in the daily 
number of tobacco cigarettes smoked between year 6 and baseline.
Outcomes Adjusted OR (95% CI) pA
Quitting any product (tobacco and/or e-cigarettes)  
A1. Analyses by baseline status, including the larger 12-month sample  
 – Tobacco only smokers (ref. cat.) 1 (–) –
 – E-cig. only users 0.99 (0.69-1.43) 0.9
 – Dual users 0.88 (0.60-1.29) 0.5
A2. Analyses by baseline status, including only the participants 
 with 6-year follow-up data  
 – Tobacco only smokers (ref. cat.) 1 (–) –
 – E-cig. only users 0.95 (0.65-1.38) 0.8
 – Dual users 0.91 (0.62-1.35) 0.6
Continuous tobacco abstinence from baseline or cessation from tobacco during follow-up  
A1. Analyses by baseline status, including the larger 12-month sample  
 – Tobacco only smokers (ref. cat.) 1 (–) –
 – E-cig. only users 3.53 (2.92-4.95) <0.001
 – Dual users 1.18 (0.84-1.65) 0.4
A2. Analyses by baseline status, including only the participants 
 with 6-year follow-up data  
 – Tobacco only smokers (ref. cat.) 1 (–) –
 – E-cig. only users 3.34 (2.37-4.70) <0.001
 – Dual users 1.22 (0.86-1.73) 0.3
Number of tobacco cig. per day - Difference 6y-baseline Adj. coefficient (95% CI) pB
A2. Analyses by baseline status, including only participants 
 with 6-year follow-up data  
 – Tobacco only smokers (ref. cat.) 0 (–) –
 – Dual users 0.43 (-0.98; 1.83) 0.6
A3. Analyses restricted to non switchers only, with all data at 72 months  
 – Tobacco only smokers (ref. cat.) 0 (–) –
 – Dual users 6.51 (3.77; 9.26) <0.001
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the quitting rates (of both tobacco and/or e-cig) 
among baseline dual users were comparable to 
those of baseline tobacco smokers (with about 
80% of dual users relapsing to tobacco smoking 
at some time during follow-up), and, in line with 
the 4-year assessment38, the reduction of tobacco 
cigarettes smoked per day was non significantly 
different between dual users and tobacco only 
smokers. In the heterogeneous scenario currently 
available, with differences in study design, ana-
lytical approaches, comparator groups and select-
ed populations, and relatively short follow-up20, 
our results support, on one side, the encourag-
ing role of e-cig alone, also in the long term, in 
helping tobacco smokers remaining abstinent, 
consistent with previous studies showing higher 
tobacco abstinence rates among e-cig users27,33 
(who were also more likely to attempt and suc-
cessfully quit23,55). On the other side, the present 
findings indicate what has been previously shown 
on the absence of any benefit when e-cig are used 
in combination with tobacco cigarettes47,56-61. In 
contrast to these findings, however, some analy-
ses showed lower tobacco abstinence rates among 
e-cig users21,24,25,28,48,62,63, or even encouraging re-
sults for dual use (higher quitting rates and lower 
relapsing rates as compared to traditional smok-
ing)23,64. Some of these studies, however, enrolled 
subjects less motivated to quit25,28,48,63; in addi-
tion, bans against e-cigarette sales62 may have 
contributed, at least in part, to the low quitting 
rates among e-cig users reported in some previ-
ous analyses65,66. Moreover, another element may 
have contributed to explain the favourable results 
achieved among dual users in some recent sur-
veys: second- or third-generation e-cig are more 
effective than older versions in nicotine delivery, 
thus reducing nicotine withdrawal symptoms and 
improving sustained nicotine abstinence38. 
A growing body of evidence33,58,59,67, although 
still limited, has focused on the pathways of use 
of e-cig or dual users, followed for a maximum 
of 3 years. In contrast with previous findings 
that most e-cig users are able to remain so58,59,67, 
and about two thirds of dual users shift to e-cig 
alone during follow-up33, we found patterns of 
use largely varying throughout the six years of 
follow-up. Less than one fifth of baseline tobac-
co smokers made an attempt to use e-cig (alone 
or in combination), while half of e-cig users, and 
more than 80% of dual users switched group at 
least once during follow-up, mostly to restart 
with tobacco smoking (alone or combined). Ad-
ditionally, once a relapse to tobacco was made, 
only a minority of baseline e-cig and dual users 
performed a further attempt to quit. However, 
more than 60% of quitting attempts proved suc-
cessful irrespective of baseline group, notably 
with no significant differences between ever and 
never e-cig users. Taken together, these findings 
add to the existing evidence6,68,69 on the dramat-
ic reluctance of tobacco smokers to change their 
habit over and beyond quitting, and suggest that, 
even when the switching pattern was kept into 
account, the use of e-cig, either alone or in com-
bination with tobacco cigarettes, did not seem to 
substantially enhance the propensity to quit. The 
higher switching rates from e-cig or dual use that 
we found in our sample may be explained, at least 
in part, by the presence in our study of multiple 
assessment performed throughout a long period 
of time, as compared to prior studies with short-
er follow-up and only baseline-endline assess-
ments33,58,59,67. This approach allowed us to literal-
ly monitor, for each patient, all changes occurred 
throughout six years, thus providing a multifac-
eted pattern, more complex to interpret but also 
more adherent to the high variability of a “real 
life” scenario. Additionally, increasing evidence 
suggests that, among former tobacco smokers, 
the use of first-generation devices (with low nic-
otine concentration) is a strong predictor of stop-
ping e-cig use to switch back to tobacco67,70,71. It is 
possible that a large proportion of baseline e-cig 
and dual users enrolled in our sample used old-
er devices. Unfortunately, however, we were not 
able to verify such hypothesis because we did not 
collect data on the type of e-cig used.
Some limitations of the study must be con-
sidered. First, although false assertions were rare 
(<10 overall, during all evaluations), part of the 
data were self-reported: we were able to confirm 
the cessation of tobacco smoking - through a test 
of carbon monoxide levels - in only 50% of the 
quitters, and only 62.8% of the participants had 
their health data checked through direct visits or 
hospital discharge abstracts. Second, 29.2% of 
the participants were lost at the first follow-up. 
However, responders and non-responders were 
comparable for most variables36, and the rate of 
subsequent losses was very low. Third, similar 
to several observational studies in the field, we 
included all types of e-cig to approach real-life 
conditions, but different e-cig models with vari-
ous nicotine doses might lead to diverse results58. 
However, the rates of tobacco abstinence and 
all-smoking cessation did not differ by nicotine 
concentration (36, 6-year data not shown), and ob-
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servational studies, which imply a free choice of 
product, may represent a better picture of the real 
world experiences72.
Conclusions
After six years of follow-up of a large sample 
of current or former smokers, the use of e-cig, 
either alone or in combination with tobacco cig-
arettes, did not significantly decrease the rate of 
diseases potentially related to tobacco, and did 
not substantially improve self-reported health. 
Although the follow-up is the longest to date, and 
the findings add to the growing evidence on the 
concerns on the health benefit of e-cig, further 
studies with follow-ups approaching a decade are 
required to elucidate the long-term impact on can-
cer or cardiovascular risk. Regarding the poten-
tial effectiveness of vaping for smoking cessation, 
the complete switch to e-cig, when persistent, did 
help tobacco quitters to remain abstinent from 
smoking, but the combined e-cig use in addition 
to tobacco smoking (dual use) did not increase 
the likelihood of either smoking cessation or re-
duction. In real-life conditions, the vast majori-
ty of dual users and half of e-cig users switched 
smoking/vaping status during the follow-up, ris-
ing important issues for the classification of these 
subjects, and suggesting that more real-life data, 
with multiple assessments, are required to im-
prove the validity of long-term observational or 
experimental studies on the effects of electronic 
and/or tobacco cigarettes, as well as most recent 
heat-not-burn tobacco products.
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E-cig. E-cig. E-cig. Tobacco Quit 1 Yes Yes Yes 
E-cig. E-cig. E-cig. E-cig. Tobacco 1 Yes No No 
E-cig. E-cig. E-cig. E-cig. E-cig. 70 No No Yes 
E-cig. E-cig. E-cig. E-cig. Dual 2 Yes No No 
E-cig. E-cig. E-cig. E-cig. Quit 2 No Yes Yes 
E-cig. E-cig. E-cig. Dual Tobacco 1 Yes No No 
E-cig. E-cig. E-cig. Quit E-cig 1 No No Yes 
E-cig. E-cig. E-cig. Quit Quit 7 No Yes Yes 
E-cig. E-cig. Dual Tobacco Tobacco 2 Yes No No 
E-cig. E-cig. Dual E-cig. E-cig. 1 Yes No Yes 
E-cig. E-cig. Dual Dual E-cig 1 Yes No Yes 
E-cig. E-cig. Dual Dual Dual 1 Yes No No 
E-cig. E-cig. Quit Tobacco Tobacco 1 Yes No No 
E-cig. E-cig. Quit Quit Tobacco 2 Yes No No 
E-cig. E-cig. Quit Quit Quit 10 No Yes Yes 
E-cig. Dual Tobacco Tobacco Tobacco 6 Yes No No 
E-cig. Dual Tobacco E-cig. E-cig. 2 Yes No Yes 
E-cig. Dual Tobacco E-cig. Dual 1 Yes No No 



















E-cig. Dual E-cig. Tobacco Quit 1 Yes Yes Yes 
E-cig. Dual E-cig. E-cig. E-cig 3 Yes No Yes 
E-cig. Dual E-cig. E-cig. Dual 1 Yes No No 
E-cig. Dual E-cig. Quit Quit 1 Yes Yes Yes 
E-cig. Dual Dual Tobacco Tobacco 2 Yes No No 
E-cig. Dual Dual E-cig. Dual 1 Yes No No 
E-cig. Dual Dual Dual Dual 5 Yes No No 
E-cig. Dual Quit Quit Quit 1 Yes Yes Yes 
E-cig. Quit Tobacco Tobacco Tobacco 2 Yes No No 
E-cig. Quit Tobacco Tobacco Quit 1 Yes Yes Yes 
E-cig. Quit Tobacco Quit Quit 2 Yes Yes Yes 
E-cig. Quit E-cig. E-cig. E-cig. 1 No No Yes 
E-cig. Quit E-cig. Quit Quit 1 No Yes Yes 
E-cig. Quit Dual Tobacco Tobacco 1 Yes No No 
E-cig. Quit Quit E-cig. E-cig. 1 No No Yes 
E-cig. Quit Quit Quit Quit 25 No Yes Yes 
Dual Tobacco Tobacco Tobacco Tobacco 71 Yes No No 
Dual Tobacco Tobacco Tobacco E-cig 1 Yes No Yes 
Dual Tobacco Tobacco Tobacco Dual 1 Yes No No 
Dual Tobacco Tobacco Tobacco Quit 6 Yes Yes Yes 
Dual Tobacco Tobacco E-cig. E-cig 1 Yes No Yes 
Dual Tobacco Tobacco E-cig. Quit 1 Yes Yes Yes 
Dual Tobacco Tobacco Dual Tobacco 3 Yes No No 
Dual Tobacco Tobacco Dual E-cig 1 Yes No Yes 
Dual Tobacco Tobacco Dual Dual 3 Yes No No 
Dual Tobacco Tobacco Quit Dual 1 Yes No No 
Dual Tobacco Tobacco Quit Quit 10 Yes Yes Yes 
Dual Tobacco E-cig. E-cig. Quit 1 Yes Yes Yes 
Dual Tobacco E-cig. Quit Quit 1 Yes Yes Yes 
Dual Tobacco Dual Tobacco Tobacco 2 Yes No No 
Dual Tobacco Dual E-cig. E-cig. 2 Yes No Yes 
Dual Tobacco Dual Dual Tobacco 1 Yes No No 
Dual Tobacco Dual Dual E-cig 1 Yes No Yes 
Dual Tobacco Dual Dual Dual 3 Yes No No 
Dual Tobacco Quit E-cig. E-cig 1 Yes No Yes 
Dual Tobacco Quit Quit Tobacco 1 Yes No No 
Dual Tobacco Quit Quit Quit 2 Yes Yes Yes 
Dual E-cig. Tobacco Tobacco Tobacco 2 Yes No No 
Dual E-cig. Tobacco E-cig. E-cig 2 Yes No Yes 
Dual E-cig. E-cig. E-cig. E-cig 12 Yes No Yes 
Dual E-cig. E-cig. Quit Quit 1 Yes Yes Yes 
Dual E-cig. Dual E-cig. E-cig. 1 Yes No Yes 



















Dual E-cig. Dual Dual Quit 1 Yes Yes Yes 
Dual E-cig. Quit Quit Quit 3 Yes Yes Yes 
Dual Dual Tobacco Tobacco Tobacco 12 Yes No No 
Dual Dual Tobacco E-cig. Quit 1 Yes Yes Yes 
Dual Dual Tobacco Quit Tobacco 1 Yes No No 
Dual Dual E-cig. Tobacco Tobacco 1 Yes No No 
Dual Dual E-cig. E-cig. E-cig 5 Yes No Yes 
Dual Dual E-cig. E-cig. Dual 1 Yes No No 
Dual Dual E-cig. Quit Quit 1 Yes Yes Yes 
Dual Dual Dual Tobacco Tobacco 5 Yes No No 
Dual Dual Dual E-cig. E-cig 1 Yes No Yes 
Dual Dual Dual Dual E-cig 1 Yes No Yes 
Dual Dual Dual Dual Dual 14 No No No 
Dual Dual Dual Dual Quit 2 No Yes Yes 
Dual Dual Quit E-cig. E-cig 1 Yes No Yes 
Dual Dual Quit Dual Dual 1 No No No 
Dual Dual Quit Quit Quit 5 No Yes Yes 
Dual Quit Tobacco Tobacco Tobacco 3 Yes No No 
Dual Quit Tobacco Tobacco Quit 1 Yes Yes Yes 
Dual Quit Tobacco Dual Tobacco 1 Yes No No 
Dual Quit Tobacco Dual Dual 1 Yes No No 
Dual Quit E-cig. E-cig. E-cig 1 Yes No Yes 
Dual Quit E-cig. Quit Quit 1 Yes Yes Yes 
Dual Quit Quit Tobacco Tobacco 2 Yes No No 
Dual Quit Quit Dual Tobacco 1 Yes No No 
Dual Quit Quit Quit Tobacco 1 Yes No No 
Dual Quit Quit Quit Quit 14 No Yes Yes 
 
Tobacco: Tobacco smoking only;  E-cig.: Electronic cigarettes use only;  Dual: Dual use, both tobacco and e-cigarettes. 
